Generics BulletinHBW InsightIn VivoMedtech InsightPink SheetScrip

Generics Bulletin

Medtech Insight

Coronavirus Update: Moderna’s Omicron Vaccine Study Successful, But Data Draw Skepticism

Jun 08 2022

• By Alaric DeArment

Moderna announced results from the Phase II/III study of its mRNA-1273.214 vaccine candidate • Source: Shutterstock

Related Content

ICER Gives Cold Shoulder To Merck/Ridgeback’s COVID-19 Pill

May 10 2022

BioNTech On The Evolving COVID-19 Vaccine Strategy

May 09 2022

Coronavirus Update: FDA Tries To Control J&J’s Vaccine, Extended Use Of Paxlovid

May 06 2022

Pfizer On Paxlovid: "There's Still A Long Way To Go"

May 03 2022

AZ's COVID-19 Antibody Combo Protects For Longer But Access Issues Persist

Apr 21 2022

COVID-19 Relapses, Lack Of Omicron Data Complicate Paxlovid Case In India

May 13 2022

Novavax Gains US FDA Advisory Committee Endorsement, But So Does Myocarditis Risk Statement

Jun 08 2022

Related Companies

Moderna, Inc.

Pfizer Inc.

BioNTech SE

Novavax, Inc.

Merck & Co., Inc.

Ridgeback Biotherapeutics LP

Additional Topics

Coronavirus COVID-19 Clinical Trials Manufacturing Research & Development BioPharmaceutical

More from COVID-19

More from Scrip

Twitter feed RSS feed RSS feed

About UsOpens in new window
Meet the TeamOpens in new window
RSS FeedOpens in new window

Contact Us
Customer Service
Subscribe
AdvertisingOpens in new window
Feedback

Terms and ConditionsOpens in new window

Privacy PolicyOpens in new window